⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12496399 | 0.76 | — | — | |
| SCHEMBL13620942 | 0.76 | — | — | |
| SCHEMBL950470 | 0.74 | — | — | |
| SCHEMBL2065243 | 0.73 | — | — | |
| SCHEMBL29954338 | 0.70 | PGR (0.33) | — | |
| SCHEMBL20195375 | 0.70 | ALDH1A1 (0.36) | — | |
| SCHEMBL14433364 | 0.68 | PGR (0.33) | — | |
| SCHEMBL12655214 | 0.68 | PGR (0.33) | — | |
| SCHEMBL4627777 | 0.67 | HCAR3 (0.32) | — | |
| SCHEMBL2812953 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453675-B2 | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-09-27 | — | — | US | disclosed |
| US-20210309661-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-10-07 | — | — | US | disclosed |
| US-10787454-B2 | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | BIAL—BioTech Investments, Inc. (PT) | 2020-09-29 | — | — | US | disclosed |
| US-20190119283-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2019-04-25 | — | — | US | disclosed |
| EP-3440083-A1 | IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Lysosomal Therapeutics Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| US-9920061-B2 | Imidazo[1,5-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170349599-A1 | IMIDAZO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-12-07 | — | — | US | disclosed |
| WO-2017176961-A1 | IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| US-9670189-B2 | Substituted condensed pyrimidine compounds | Grünenthal GmbH (DE) | 2017-06-06 | — | — | US | disclosed |
| EP-2951173-B1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2017-05-17 | — | — | EP | disclosed |
| EP-2184994-B1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2184994-B1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130236481-A1 | HETEROCYCLE -ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130236481-A1 | HETEROCYCLE -ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8435996-B2 | Heterocycle-aryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435996-B2 | Heterocycle-aryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-11 | — | — | US | disclosed |
| EP-2184994-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009017818-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |